128 related articles for article (PubMed ID: 7913500)
1. Role of the 5-HT2 receptor in the methamphetamine-induced neurochemical alterations.
Johnson M; Sonsalla PK; Letter AA; Hanson GR; Gibb JW
J Pharmacol Exp Ther; 1994 Jul; 270(1):97-103. PubMed ID: 7913500
[TBL] [Abstract][Full Text] [Related]
2. Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine.
Johnson M; Mitros K; Stone DM; Zobrist R; Hanson GR; Gibb JW
J Pharmacol Exp Ther; 1992 May; 261(2):586-91. PubMed ID: 1374469
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain.
Hotchkiss AJ; Gibb JW
J Pharmacol Exp Ther; 1980 Aug; 214(2):257-62. PubMed ID: 6104722
[TBL] [Abstract][Full Text] [Related]
4. The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain.
Gibb JW; Stone DM; Stahl DC; Hanson GR
NIDA Res Monogr; 1987; 76():316-21. PubMed ID: 2449619
[TBL] [Abstract][Full Text] [Related]
5. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum.
Bowyer JF; Tank AW; Newport GD; Slikker W; Ali SF; Holson RR
J Pharmacol Exp Ther; 1992 Feb; 260(2):817-24. PubMed ID: 1346646
[TBL] [Abstract][Full Text] [Related]
6. Exacerbation of methamphetamine-induced neurochemical deficits by melatonin.
Gibb JW; Bush L; Hanson GR
J Pharmacol Exp Ther; 1997 Nov; 283(2):630-5. PubMed ID: 9353379
[TBL] [Abstract][Full Text] [Related]
7. Effects of dopaminergic and serotonergic receptor blockade on neurochemical changes induced by acute administration of methamphetamine and 3,4-methylenedioxymethamphetamine.
Johnson M; Hanson GR; Gibb JW
Neuropharmacology; 1988 Nov; 27(11):1089-96. PubMed ID: 3144655
[TBL] [Abstract][Full Text] [Related]
8. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats.
Schmidt CJ; Abbate GM; Black CK; Taylor VL
J Pharmacol Exp Ther; 1990 Nov; 255(2):478-83. PubMed ID: 1978728
[TBL] [Abstract][Full Text] [Related]
9. Increases of substance P-like immunoreactivity within striatal-nigral structures after subacute methamphetamine treatment.
Ritter JK; Schmidt CJ; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1984 May; 229(2):487-92. PubMed ID: 6201607
[TBL] [Abstract][Full Text] [Related]
10. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration.
Fleckenstein AE; Wilkins DG; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1997 Oct; 283(1):281-5. PubMed ID: 9336334
[TBL] [Abstract][Full Text] [Related]
11. Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: comparison with acute haloperidol effects.
Merchant KM; Hanson GR; Dorsa DM
J Pharmacol Exp Ther; 1994 May; 269(2):806-12. PubMed ID: 8182549
[TBL] [Abstract][Full Text] [Related]
12. Response of extrapyramidal and limbic neuropeptides to fenfluramine administration: comparison with methamphetamine.
Hanson GR; Singh N; Bush L; Gibb JW
J Pharmacol Exp Ther; 1991 Dec; 259(3):1197-202. PubMed ID: 1722253
[TBL] [Abstract][Full Text] [Related]
13. Effects of a single dose of methamphetamine and iprindole on the serotonergic and dopaminergic system of the rat brain.
Peat MA; Warren PF; Gibb JW
J Pharmacol Exp Ther; 1983 Apr; 225(1):126-31. PubMed ID: 6187915
[TBL] [Abstract][Full Text] [Related]
14. Prenatal methamphetamine attenuates serotonin mediated renin secretion in male and female rat progeny: evidence for selective long-term dysfunction of serotonin pathways in brain.
Cabrera TM; Levy AD; Li Q; van de Kar LD; Battaglia G
Synapse; 1993 Nov; 15(3):198-208. PubMed ID: 8278897
[TBL] [Abstract][Full Text] [Related]
15. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade.
Saller CF; Czupryna MJ; Salama AI
J Pharmacol Exp Ther; 1990 Jun; 253(3):1162-70. PubMed ID: 2141636
[TBL] [Abstract][Full Text] [Related]
16. Role of dopamine in the neurotoxic effects of methamphetamine.
Schmidt CJ; Ritter JK; Sonsalla PK; Hanson GR; Gibb JW
J Pharmacol Exp Ther; 1985 Jun; 233(3):539-44. PubMed ID: 2409267
[TBL] [Abstract][Full Text] [Related]
17. Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens.
Wagstaff JD; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1996 Aug; 278(2):547-54. PubMed ID: 8768703
[TBL] [Abstract][Full Text] [Related]
18. Further studies of the role of hyperthermia in methamphetamine neurotoxicity.
Bowyer JF; Davies DL; Schmued L; Broening HW; Newport GD; Slikker W; Holson RR
J Pharmacol Exp Ther; 1994 Mar; 268(3):1571-80. PubMed ID: 8138969
[TBL] [Abstract][Full Text] [Related]
19. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents.
Albers DS; Sonsalla PK
J Pharmacol Exp Ther; 1995 Dec; 275(3):1104-14. PubMed ID: 8531070
[TBL] [Abstract][Full Text] [Related]
20. Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems.
Johnson M; Elayan I; Hanson GR; Foltz RL; Gibb JW; Lim HK
J Pharmacol Exp Ther; 1992 May; 261(2):447-53. PubMed ID: 1349640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
